These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16216993)

  • 1. Eplerenone antagonizes atherosclerosis, but what is the agonist?
    Strawn WB
    Hypertension; 2005 Nov; 46(5):1093-4. PubMed ID: 16216993
    [No Abstract]   [Full Text] [Related]  

  • 2. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.
    Ye P; Yamashita T; Pollock DM; Sasano H; Rainey WE
    Horm Metab Res; 2009 Jan; 41(1):35-9. PubMed ID: 18819053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
    Raz-Pasteur A; Gamliel-Lazarovich A; Gantman A; Coleman R; Keidar S
    J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):228-35. PubMed ID: 23223089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice.
    Raz-Pasteur A; Gamliel-Lazarovich A; Coleman R; Keidar S
    J Cardiovasc Pharmacol; 2012 Dec; 60(6):508-12. PubMed ID: 23232789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
    Rogerson FM; Yao Y; Smith BJ; Fuller PJ
    Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.
    Łabuzek K; Liber S; Bułdak Ł; Krupej-Kędzierska J; Machnik G; Bobrzyk M; Okopień B
    Eur J Pharmacol; 2014 Mar; 726():96-108. PubMed ID: 24486397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity.
    Pojoga LH; Baudrand R; Adler GK
    Eur Heart J; 2013 Dec; 34(45):3475-7. PubMed ID: 23666249
    [No Abstract]   [Full Text] [Related]  

  • 11. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
    Imanishi T; Ikejima H; Tsujioka H; Kuroi A; Kobayashi K; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    Hypertension; 2008 Mar; 51(3):734-41. PubMed ID: 18227404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone--a novel selective aldosterone blocker.
    Zillich AJ; Carter BL
    Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Roll of aldosterone in pathogenesis of kidney disorders].
    Kitamura K; Tomita K
    Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1428-34. PubMed ID: 16097603
    [No Abstract]   [Full Text] [Related]  

  • 15. Mineralocorticoid receptor antagonism in experimental atherosclerosis.
    Rajagopalan S; Duquaine D; King S; Pitt B; Patel P
    Circulation; 2002 May; 105(18):2212-6. PubMed ID: 11994257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension and the mineralocorticoid receptor in the brain.
    Gómez Sánchez EP
    Ann N Y Acad Sci; 1994 Nov; 746():415-7. PubMed ID: 7825903
    [No Abstract]   [Full Text] [Related]  

  • 17. Eplerenone does not attenuate diabetes-associated atherosclerosis.
    Koh PJ; Koitka A; Cooper ME; Allen TJ
    J Hypertens; 2009 Jul; 27(7):1431-8. PubMed ID: 19381106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
    Sica DA
    Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?
    Hermidorff MM; Faria Gde O; Amâncio Gde C; de Assis LV; Isoldi MC
    Biochem Cell Biol; 2015 Feb; 93(1):83-93. PubMed ID: 25488178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.
    Loan Le TY; Mardini M; Howell VM; Funder JW; Ashton AW; Mihailidou AS
    Hypertension; 2012 Jun; 59(6):1164-9. PubMed ID: 22508833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.